Pharmacological Management of Heart Failure

Correct Answer

B — Furosemide

Rationale

Furosemide is a loop diuretic, named for its site of action in the thick ascending limb of the loop of Henle in the kidney. Hydrochlorothiazide is a thiazide diuretic that acts at the distal convoluted tubule. Spironolactone is a mineralocorticoid receptor antagonist (potassium-sparing diuretic) that acts at the collecting duct. Acetazolamide is a carbonic anhydrase inhibitor that acts at the proximal tubule.

Correct Answer

D — Spironolactone

Rationale

Spironolactone is a mineralocorticoid receptor antagonist, a drug class that blocks the aldosterone receptor in the kidney and heart. Furosemide is a loop diuretic. Enalapril is an angiotensin-converting enzyme inhibitor. Metoprolol succinate is a selective beta-1 adrenergic receptor antagonist. Knowing the class label for each drug is sufficient to answer this question.

Correct Answer

C — Sacubitril/valsartan

Rationale

Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor, a combination drug that blocks both the angiotensin receptor (valsartan component) and the enzyme neprilysin (sacubitril component). Lisinopril is an angiotensin-converting enzyme inhibitor. Losartan is an angiotensin receptor blocker. Aliskiren is a direct renin inhibitor. These four drugs all act on the renin-angiotensin-aldosterone system but at distinct points and with distinct class labels.

Correct Answer

A — Carvedilol

Rationale

Carvedilol is a non-selective beta-adrenergic receptor antagonist, meaning it blocks both beta-1 and beta-2 receptors. It also has alpha-1 blocking activity. Metoprolol succinate and bisoprolol are selective beta-1 adrenergic receptor antagonists. Atenolol is also a selective beta-1 antagonist and is not among the three agents approved for heart failure with reduced ejection fraction. The three approved agents are carvedilol, metoprolol succinate, and bisoprolol.

Correct Answer

C — Dapagliflozin

Rationale

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, a drug class named for the transporter it blocks in the kidney. Empagliflozin is the other sodium-glucose cotransporter 2 inhibitor used in heart failure; dapagliflozin and empagliflozin are the two agents recommended in current guidelines. Ivabradine is a funny current (Iₙ) channel blocker. Vericiguat is a soluble guanylate cyclase stimulator. Hydralazine is a direct arterial vasodilator. None of these three belong to the sodium-glucose cotransporter 2 inhibitor class.

Correct Answer

B — Carvedilol, metoprolol succinate, and bisoprolol

Rationale

The three beta-blockers with proven mortality benefit in heart failure with reduced ejection fraction are carvedilol, metoprolol succinate, and bisoprolol. These three agents are not interchangeable with other beta-blockers for this indication — the evidence base is specific to these drugs. Atenolol and propranolol are not among the approved agents. Metoprolol tartrate is a short-acting formulation that is also not interchangeable with metoprolol succinate (the extended-release formulation) for this indication.

Correct Answer

A — It increases systemic vascular resistance and directly promotes cardiac hypertrophy and fibrosis

Rationale

Chronically elevated angiotensin II harms the failing heart in two related ways. First, it causes sustained vasoconstriction, raising systemic vascular resistance (afterload) and increasing the work the weakened ventricle must do to eject blood. Second, angiotensin II directly promotes hypertrophy (thickening) and fibrosis (scarring) of the cardiac muscle, accelerating the structural deterioration called cardiac remodeling. Option B describes the sympathetic nervous system effect (mediated by norepinephrine at beta-1 receptors), not angiotensin II. Option C misidentifies the relationship — neprilysin breaks down natriuretic peptides; angiotensin II has no inhibitory effect on neprilysin. Option D reverses the physiology — angiotensin II promotes aldosterone release, which drives sodium and water retention (increasing preload), not excretion.

Correct Answer

D — Neprilysin inhibition slows the breakdown of natriuretic peptides, amplifying their protective counter-regulatory effects

Rationale

Neprilysin is an enzyme that degrades natriuretic peptides, including atrial natriuretic peptide and B-type natriuretic peptide. By inhibiting neprilysin, sacubitril (the neprilysin-inhibiting component of sacubitril/valsartan) slows this degradation, allowing natriuretic peptide levels to rise and their beneficial effects — sodium excretion, vasodilation, and anti-fibrotic signaling — to be amplified. This is why neprilysin inhibition must be combined with angiotensin receptor blockade: neprilysin inhibition alone would also prevent the breakdown of angiotensin II-generating substrates, which is why the valsartan component is essential. Option A describes the mechanism of angiotensin-converting enzyme inhibitors, not neprilysin inhibition. Options B and C describe separate mechanisms unrelated to neprilysin.

Correct Answer

B — Chronic catecholamine excess directly injures cardiac muscle cells, and beta-blockade interrupts this ongoing damage

Rationale

The short-term response to reduced cardiac output includes sympathetic nervous system activation, which raises heart rate and contractility through norepinephrine acting at beta-1 adrenergic receptors. This response is helpful acutely. When sustained chronically, however, elevated norepinephrine (catecholamine) levels directly injure cardiac muscle cells, reduce the heart's responsiveness to further sympathetic stimulation, and increase the risk of arrhythmias. Plasma norepinephrine levels in heart failure correlate with mortality. Blocking the beta-1 receptor interrupts this toxic catecholamine signaling and, over months, allows the heart to partially recover — a process called reverse remodeling. Option A overstates the alpha-1 mechanism: beta-blockers do not increase cardiac output through alpha-1 blockade (though carvedilol does have some alpha-1 blocking activity, its benefit in heart failure is not through this mechanism). Options C and D describe mechanisms of other drug classes.

Correct Answer

C — They increase sodium and water excretion by the kidney, reducing intravascular volume and preload

Rationale

Congestion in heart failure — manifesting as shortness of breath, edema, and elevated filling pressures — results from excess sodium and water retained in the body. Loop diuretics act at the thick ascending limb of the loop of Henle in the kidney, blocking the sodium-potassium-2-chloride cotransporter and dramatically increasing the excretion of sodium and water in the urine. This reduces intravascular volume, which lowers the preload (filling pressure) on the heart and relieves congestion. Loop diuretics are the primary agents for acute symptom relief in heart failure. Option A describes the mechanism of mineralocorticoid receptor antagonists such as spironolactone and eplerenone. Option B describes the mechanism of angiotensin-converting enzyme inhibitors. Option D is not a mechanism of loop diuretics.

Correct Answer

A — Aldosterone acting at the mineralocorticoid receptor promotes cardiac fibrosis, and blocking this receptor reduces fibrosis independently of diuresis

Rationale

Aldosterone has two important effects in heart failure. First, it acts at mineralocorticoid receptors in the kidney's collecting duct to promote sodium and water retention — the effect that gives this drug class its diuretic benefit when blocked. Second, and more important for long-term survival, aldosterone acts at mineralocorticoid receptors in the heart and other tissues to independently promote fibrosis (scarring) of the cardiac muscle. This fibrotic effect accelerates cardiac remodeling and worsens heart failure progression. By blocking the mineralocorticoid receptor, spironolactone and eplerenone prevent this aldosterone-driven fibrosis, providing a survival benefit beyond simple fluid management. Options B, C, and D each describe mechanisms of different drug classes — beta-blockers, angiotensin-converting enzyme inhibitors, and a mischaracterization of natriuretic peptide biology, respectively.

Correct Answer

D — They interrupt the neurohormonal cascade driving cardiac remodeling, allowing partial reversal of ventricular structural deterioration

Rationale

The key insight from heart failure drug trials is that guideline-directed medical therapy does not simply control symptoms — it can partially reverse the cardiac remodeling process. By blocking the renin-angiotensin-aldosterone system and sympathetic nervous system activation that drives remodeling, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, sacubitril/valsartan, and beta-blockers allow the ventricle to partially shrink back toward a more normal shape and size, and ejection fraction can measurably improve over months of therapy. This reverse remodeling effect is the structural basis for their survival benefit. Option A describes inotropic drugs such as dobutamine — these increase contractility but do not produce reverse remodeling and carry risks in chronic use. Option B is an incomplete explanation; reducing heart rate alone does not account for the survival benefit. Option C reverses the physiological effect — increasing preload worsens the failing heart's condition, not improves it.

Correct Answer

B — Sodium-glucose cotransporter 2 inhibitors

Rationale

Sodium-glucose cotransporter 2 inhibitors — specifically dapagliflozin and empagliflozin — are the first drug class to demonstrate benefit in heart failure with preserved ejection fraction. The four-pillar framework of guideline-directed medical therapy (renin-angiotensin-aldosterone system blockers, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors) was originally developed and proven in heart failure with reduced ejection fraction. Heart failure with preserved ejection fraction proved resistant to these same therapies for many years. Sodium-glucose cotransporter 2 inhibitors changed this, making them particularly important in this growing population. The full pharmacology of sodium-glucose cotransporter 2 inhibitors in heart failure is covered in Module 5.

Correct Answer

C — It directly dilates arterial blood vessels through a mechanism independent of the renin-angiotensin-aldosterone system

Rationale

Hydralazine is a direct arterial vasodilator. It relaxes arterial smooth muscle through a mechanism that does not involve the renin-angiotensin-aldosterone system or adrenergic receptors. By dilating the arterial system, hydralazine lowers systemic vascular resistance, which reduces afterload — the resistance the heart must overcome to eject blood. This makes hydralazine useful in patients who cannot tolerate angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (for example, due to angioedema or pregnancy). It is most often combined with isosorbide dinitrate (a venous dilator) to provide both afterload and preload reduction. Option A describes the mechanism of angiotensin receptor blockers. Option B describes the mechanism of neprilysin inhibition (the sacubitril component of sacubitril/valsartan). Option D describes the mechanism of alpha-1 adrenergic receptor antagonists such as prazosin.

Correct Answer

A — Chronic catecholamine excess directly injures cardiac muscle and increases arrhythmia risk; blocking the beta-1 receptor interrupts this ongoing toxicity

Rationale

When cardiac output falls in heart failure, the sympathetic nervous system activates as a compensatory response. Sustained elevation of catecholamines (norepinephrine and epinephrine) acting at beta-1 adrenergic receptors in the heart directly injures cardiac muscle cells, reduces the heart's responsiveness to further stimulation, and increases arrhythmia risk. Plasma norepinephrine levels in heart failure correlate with mortality. By blocking the beta-1 receptor, carvedilol and the other approved beta-blockers interrupt this catecholamine-mediated toxicity. Over months of therapy, the heart can partially recover its structure and function — a process called reverse remodeling — and ejection fraction often measurably improves. Option B describes a secondary effect of some beta-blockers on renin release, but this secondary effect does not account for the survival benefit seen in clinical trials. Options C and D describe mechanisms not associated with beta-adrenergic receptor blockade.

Correct Answer

C — Sacubitril inhibits neprilysin, slowing breakdown of natriuretic peptides, while valsartan blocks angiotensin II receptors

Rationale

Sacubitril/valsartan targets two separate arms of neurohormonal excess in heart failure. The sacubitril component inhibits neprilysin, the enzyme that degrades natriuretic peptides. Slowing this degradation raises natriuretic peptide levels, amplifying their protective effects: sodium excretion, vasodilation, and anti-fibrotic signaling. The valsartan component blocks the angiotensin II receptor, interrupting the renin-angiotensin-aldosterone system's harmful effects on the heart and vasculature. Neprilysin inhibition cannot be used without simultaneous angiotensin receptor blockade, because neprilysin also degrades angiotensin I and angiotensin II precursors — giving neprilysin inhibition alone could paradoxically raise angiotensin II activity. The combination resolves this by blocking the angiotensin receptor directly. Option A misidentifies the components: sacubitril does not inhibit angiotensin-converting enzyme, and valsartan does not block mineralocorticoid receptors. Options B and D describe mechanisms not associated with either drug component.

Correct Answer

B — Sodium-glucose cotransporter 2 inhibitors

Rationale

Heart failure with preserved ejection fraction proved resistant to drug therapies that improve survival in heart failure with reduced ejection fraction. For many years, no drug class demonstrated clear mortality or hospitalization benefit in this population. Sodium-glucose cotransporter 2 inhibitors — dapagliflozin and empagliflozin — are the first drug class to change this, making them particularly important for patients like this woman. Angiotensin-converting enzyme inhibitors and beta-blockers, while cornerstones of heart failure with reduced ejection fraction therapy, have not shown equivalent survival benefit in heart failure with preserved ejection fraction. Loop diuretics relieve congestion symptoms in both heart failure types but do not have the same evidence of modifying disease progression. The full pharmacology of sodium-glucose cotransporter 2 inhibitors in both heart failure phenotypes is covered in Module 5.

Correct Answer

D — Blocking the renin-angiotensin-aldosterone system and sympathetic nervous system interrupts the neurohormonal cascade that drives ongoing structural deterioration, allowing partial reversal of cardiac remodeling

Rationale

Cardiac remodeling — the progressive dilation, hypertrophy, and fibrosis of the failing ventricle — is driven by sustained neurohormonal activation, primarily through the renin-angiotensin-aldosterone system and the sympathetic nervous system. Left unchecked, this cycle is self-amplifying: worsening geometry increases wall stress, which further activates these systems, which drives further remodeling. By blocking the renin-angiotensin-aldosterone system (lisinopril) and the sympathetic nervous system (carvedilol), guideline-directed medical therapy interrupts this cycle. Over months, the ventricle can partially recover its shape and contractile function — a process called reverse remodeling — which is why these drug classes improve survival rather than only relieving symptoms. Option A describes a metabolic mechanism of sodium-glucose cotransporter 2 inhibitors that contributes to their benefit, but reverse remodeling in heart failure with reduced ejection fraction is primarily attributable to renin-angiotensin-aldosterone system and sympathetic blockade. Options B and C describe mechanisms that do not apply to the drugs named.